These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 21220747)

  • 1. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia.
    Warsch W; Kollmann K; Eckelhart E; Fajmann S; Cerny-Reiterer S; Hölbl A; Gleixner KV; Dworzak M; Mayerhofer M; Hoermann G; Herrmann H; Sillaber C; Egger G; Valent P; Moriggl R; Sexl V
    Blood; 2011 Mar; 117(12):3409-20. PubMed ID: 21220747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.
    Quentmeier H; Eberth S; Romani J; Zaborski M; Drexler HG
    J Hematol Oncol; 2011 Feb; 4():6. PubMed ID: 21299849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia.
    Aranda-Tavío H; Recio C; Martín-Acosta P; Guerra-Rodríguez M; Brito-Casillas Y; Blanco R; Junco V; León J; Montero JC; Gandullo-Sánchez L; McNaughton-Smith G; Zapata JM; Pandiella A; Amesty A; Estévez-Braun A; Fernández-Pérez L; Guerra B
    Biomed Pharmacother; 2021 Dec; 144():112330. PubMed ID: 34673425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells.
    Bolton-Gillespie E; Schemionek M; Klein HU; Flis S; Hoser G; Lange T; Nieborowska-Skorska M; Maier J; Kerstiens L; Koptyra M; Müller MC; Modi H; Stoklosa T; Seferynska I; Bhatia R; Holyoake TL; Koschmieder S; Skorski T
    Blood; 2013 May; 121(20):4175-83. PubMed ID: 23543457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent STAT5-mediated ROS production and involvement of aberrant p53 apoptotic signaling in the resistance of chronic myeloid leukemia to imatinib.
    Cheng Y; Hao Y; Zhang A; Hu C; Jiang X; Wu Q; Xu X
    Int J Mol Med; 2018 Jan; 41(1):455-463. PubMed ID: 29115375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of the interferon regulatory factor-8 (IRF-8) tumor suppressor gene by the signal transducer and activator of transcription 5 (STAT5) transcription factor in chronic myeloid leukemia.
    Waight JD; Banik D; Griffiths EA; Nemeth MJ; Abrams SI
    J Biol Chem; 2014 May; 289(22):15642-52. PubMed ID: 24753251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
    Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
    Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells.
    Grimaudo S; Meli M; Di Cristina A; Ferro A; Pipitone MR; Romagnoli R; Simoni D; Dieli F; Tolomeo M
    Anticancer Drugs; 2013 Apr; 24(4):384-93. PubMed ID: 23370613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.
    Yokota A; Kimura S; Masuda S; Ashihara E; Kuroda J; Sato K; Kamitsuji Y; Kawata E; Deguchi Y; Urasaki Y; Terui Y; Ruthardt M; Ueda T; Hatake K; Inui K; Maekawa T
    Blood; 2007 Jan; 109(1):306-14. PubMed ID: 16954504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
    Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M; Nguyen TK; Dent P; Grant S
    Mol Pharmacol; 2007 Sep; 72(3):788-95. PubMed ID: 17595328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.
    Hantschel O; Warsch W; Eckelhart E; Kaupe I; Grebien F; Wagner KU; Superti-Furga G; Sexl V
    Nat Chem Biol; 2012 Jan; 8(3):285-93. PubMed ID: 22286129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia.
    Klemm L; Duy C; Iacobucci I; Kuchen S; von Levetzow G; Feldhahn N; Henke N; Li Z; Hoffmann TK; Kim YM; Hofmann WK; Jumaa H; Groffen J; Heisterkamp N; Martinelli G; Lieber MR; Casellas R; Müschen M
    Cancer Cell; 2009 Sep; 16(3):232-45. PubMed ID: 19732723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia.
    Warsch W; Grundschober E; Berger A; Gille L; Cerny-Reiterer S; Tigan AS; Hoelbl-Kovacic A; Valent P; Moriggl R; Sexl V
    Oncotarget; 2012 Dec; 3(12):1669-87. PubMed ID: 23458731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of BCR-ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype.
    Grant H; Jiang X; Stebbing J; Foroni L; Craddock C; Griffiths M; Clark RE; O'Brien S; Khorashad JS; Gerrard G; Wang L; Irving JA; Wang M; Karran L; Dyer MJ; Forrest D; Page K; Eaves CJ; Woolfson A
    Leukemia; 2010 Oct; 24(10):1817-21. PubMed ID: 20739956
    [No Abstract]   [Full Text] [Related]  

  • 18. Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.
    Gleixner KV; Schneeweiss M; Eisenwort G; Berger D; Herrmann H; Blatt K; Greiner G; Byrgazov K; Hoermann G; Konopleva M; Waliul I; Cumaraswamy AA; Gunning PT; Maeda H; Moriggl R; Deininger M; Lion T; Andreeff M; Valent P
    Haematologica; 2017 Sep; 102(9):1519-1529. PubMed ID: 28596283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells.
    Tsubaki M; Takeda T; Kino T; Sakai K; Itoh T; Imano M; Nakayama T; Nishio K; Satou T; Nishida S
    Oncotarget; 2017 Jun; 8(24):38717-38730. PubMed ID: 28418880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. E255K and G250E mutation appearing in a patient with e19a2 chronic myeloid leukemia resistant to imatinib.
    Li C; Wang Y; Xu D; Zhang P; Ding X; Zhang N; Xiao M; Huang L; Meng L
    Clin Lab; 2015; 61(1-2):183-6. PubMed ID: 25807654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.